Stuart A. Aaronson

Last updated
Stuart A. Aaronson
Nci-vol-8199-300 Stuart Aaronson.jpg
Born (1942-02-28) February 28, 1942 (age 83)
Mount Clemens, Michigan, United States
Education UC Berkeley, UC SF
Occupation Biologist
Employer The Mount Sinai Hospital
Known for Cancer research
TitleJane B. and Jack R. Aron Professor of Neoplastic Diseases and Founding Chair Emeritus of Oncological Sciences

Stuart A. Aaronson (born February 28, 1942) is an American author and cancer biologist. [1] [2] He was the Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Chairman of Oncological Sciences at Mount Sinai Hospital, New York. [3]

Contents

Biography

Aaronson graduated summa cum laude from the University of California, Berkeley, in 1962, with a degree in chemistry. He earned his M.D. from the University of California, San Francisco Medical Center in 1966, and completed a fellowship at the University of Cambridge in England and an internship in medicine at Moffitt Hospital in San Francisco. [3]

In 1967, Aaronson joined the National Institutes of Health as a Senior Staff Fellow. He headed the Molecular Biology Section of the Viral Carcinogenesis Branch from 1970 until 1977, after which he became Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute, until 1993, when he was named Chairman of Oncological Sciences at The Mount Sinai Hospital.[ citation needed ]

Research

Aaronson's early research established the transformation-competent but replication-defective nature of mammalian sarcoma viruses and molecularly cloned many of their oncogenes. [3] [4] His investigations of the v-sis oncogene established the first normal function of an oncogene and its role in growth factor signaling. [1] [2] His discovery of erbB2 as a v-erbB-related gene amplified in a human breast carcinoma and the demonstration of its transforming properties paved the way for targeted therapies directed against its product, [4] and his successful isolation of KGF (FGF7), a growth factor present in the epithelialization-phase of wound healing, led to Amgen's successful phase III clinical trial and FDA approval of KGF for treatment of mucositis. [5] [6] Current research includes investigations into the mechanisms by which tumor suppressor genes induce permanent growth arrest/senescence, the signaling pathways involved, and investigations of the autocrine and paracrine acting growth factors PDGF, KGF, HGF, and Wnt ligands. [3]

To date, three papers on which Aaronson is author have been retracted, and two papers which he authored have received expressions of concern. [7]

Publications

Partial list:

References

  1. 1 2 "ACGT - Scientific Advisory Council - Stuart A. Aaronson, M.D." Archived from the original on June 5, 2013. Retrieved 2010-01-06.
  2. 1 2 "Breast Cancer Research Foundation: Stuart Aaronson". Archived from the original on June 20, 2010. Retrieved 2010-01-06.
  3. 1 2 3 4 "The Mount Sinai Hospital - Faculty profile" . Retrieved 2010-01-06.
  4. 1 2 "The Black Family Stem Cell Institute" . Retrieved 2010-01-06.
  5. ↑ "Human Keratinocyte Growth Factor (KGF) from GenWay Biotech, Inc". Biocompare. Retrieved 2010-01-06.
  6. ↑ Ulich, T. R.; Yi, E. S.; Cardiff, R.; Yin, S.; Bikhazi, N.; Biltz, R.; Morris, C. F.; Pierce, G. F. (May 1994). "Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor". The American Journal of Pathology. 144 (5): 862–868. PMC   1887355 . PMID   8178937.
  7. ↑ "Retraction Watch Database".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.